ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0856

Time to Renal Insufficiency Based on Prior Hydroxychloroquine Blood Levels

Michelle Petri1 and Jessica Li2, 1Johns Hopkins University School of Medicine, Timonium, MD, 2Johns Hopkins University, Baltimore, MD

Meeting: ACR Convergence 2020

Keywords: Renal, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 7, 2020

Title: SLE – Treatment Poster I

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Hydroxychloroquine (HCQ) dosing is reduced in those with renal insufficiency according to guidelines (Marmor MF, et al. Ophthalmology 2016;123:1386–94) as it is partially cleared by the kidneys.  Some studies have found that HCQ use might protect against end stage renal disease.  We explored these issues using HCQ blood levels.

Methods: Hydroxychloroquine blood levels were measured by liquid chromatography-tandem mass spectrometry as described by Füzéry et al (Clin Chim Acta 2013;421:79–84). Renal insufficiency was defined as GFR < 50% or creatinine > 1.5 mg/mL.  At least one HCQ blood level was measured at a clinic visit in 1,066 patients. Excluding patients with prior renal insufficiency (275) and missing information (6), there were 785 patients eligible for analysis, contributing 34,046 person months. There were 71 incident renal insufficiency events after the first HCQ blood level measurement. For this analysis, a dataset with one record for each month of follow up for each person were constructed. Patients were followed from first measure of HCQ blood levels to their first incident renal insufficiency or their last recorded visit with HCQ blood levels.  To calculate the rate of renal insufficiency in each demographic or clinical subgroup, the number of renal insufficiency events was divided by the number of person months at risk and then converted to rates per 1,000 person years. Pooled logistic regression was used to assess the relationship between HCQ blood levels and rates of renal insufficiency.

Results: All patients met revised ACR or SLICC classification criteria and were 93.2% female, 41% African-American, and 47.8% Caucasian. Table 1 shows the association between patient characteristics and the rate of renal insufficiency. The categories of HCQ blood levels (mean or most recent) were divided into tertiles, each containing a third of the person-years, to see if there were any trends of HCQ blood levels in incident renal insufficiency.  Table 2 shows the association between HCQ blood levels tertiles and the rate of renal insufficiency. The rate of renal insufficiency increased with HCQ blood levels. Next, the HCQ blood levels were modeled as continuous variables (Table 3).  There were significant associations between HCQ blood levels and incident renal insufficiency. The associations persisted after adjustment of covariates.

Conclusion: HCQ blood levels clearly rose in those with renal insufficiency, whether we looked at the most recent level before renal insufficiency or the mean of all prior HCQ blood levels.  Disappointingly, HCQ blood levels at the mid or high tertile did not reduce later renal insufficiency. Thus, our data do not support that HCQ would reduce end stage renal disease.  Renal insufficiency was associated with higher HCQ blood levels, likely due to reduced HCQ renal clearance, justifying the recommendation to reduce dose in those with chronic kidney disease.

Rates of renal insufficiency events by demographics and patients characteristics

Rates of renal insufficiency events by HCQ blood levels

Association between HCQ levels and renal insufficiency


Disclosure: M. Petri, Astrazeneca, 2, 5, Exagen, 2, 5, GlaxoSmithKline (GSK), 2, 5, Eli Lilly and Company, 2, 5, AbbVie Inc., 5, Aleon Pharma International, Inc, 5, Amgen, 5, Annenberg Center for Health Sciences,, 5, Blackrock Pharma, 5, Bristol Myers Squibb, 5, Decision Resources, 5, Glenmark Pharmaceuticals, 5, INOVA, 5, IQVIA, 5, Janssen Pharmaceutical, 5, Merck EMD Serono, 5, Novartis, 5, Sanofi Japan, 5, Thermofisher, 5, UCB, 5; J. Li, None.

To cite this abstract in AMA style:

Petri M, Li J. Time to Renal Insufficiency Based on Prior Hydroxychloroquine Blood Levels [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/time-to-renal-insufficiency-based-on-prior-hydroxychloroquine-blood-levels/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/time-to-renal-insufficiency-based-on-prior-hydroxychloroquine-blood-levels/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology